Free Trial

Guardant Health Q3 2023 Earnings Report

Guardant Health logo
$31.67 +0.54 (+1.73%)
(As of 12/20/2024 05:16 PM ET)

Guardant Health EPS Results

Actual EPS
-$0.73
Consensus EPS
-$0.93
Beat/Miss
Beat by +$0.20
One Year Ago EPS
N/A

Guardant Health Revenue Results

Actual Revenue
$143.03 million
Expected Revenue
$137.25 million
Beat/Miss
Beat by +$5.78 million
YoY Revenue Growth
N/A

Guardant Health Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Your chance to get on the next “60-Second Trade” (Ad)

Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!

Just head over here!
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Guardant Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Guardant Health and other key companies, straight to your email.

About Guardant Health

Guardant Health (NASDAQ:GH), a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

View Guardant Health Profile

More Earnings Resources from MarketBeat

Upcoming Earnings